Protara Therapeutics provided an update on the STARBORN - 1 Clinical Trial on November 19, 2025.
The presentation included forward-looking statements regarding the company's product candidates and development plans.
Key figures in the presentation included co-founders and key executives.
Pre-Clinical Studies
Currently in pre-clinical studies to define dosing and initiate Phase 2 trial cohort.
Orphan Drug Designations
Granted Orphan Drug Designations by the U.S. FDA for specific treatments.
Rare Pediatric Disease Designation
TARA-002 granted Rare Pediatric Disease designation by the U.S. FDA and orphan drug designation by the European Commission for the treatment of LMs.
Trial Inclusions
STARBORN - 1 trial includes BCG-Exposed patients and offers multiple upcoming opportunities.
- The presentation highlighted Protara's robust pipeline with multiple upcoming opportunities in different phases of development.
- Key designations received reflect the company's focus on addressing specific medical needs and advancing treatments.
- The inclusion of specific patient groups in trials indicates a comprehensive approach to research and development.
Protara Therapeutics showcased promising developments in its clinical trials and outlined a strategic roadmap for its product candidates.